The drug delivery and biomaterial attributes of the ATRIGEL® technology in the treatment of periodontal disease

Expert Opinion on Investigational Drugs

Volumn 7, Issue 9, 1998, Pages 1483-1491

  Southard, G L ^a   Dunn, R L ^a   Garrett, S ^a  

^a QLT Inc   (United States)

Author keywords

ATRIDOX ; ATRIGEL ; ATRISORB ; Biomaterial; Chronic infection; Chronic inflammation; Clinical trials; Drug delivery; Periodontal disease; Systemic disease

Indexed keywords

ATRIDOX; ATRIGEL; ATRISORB; BONE MORPHOGENETIC PROTEIN; DOXYCYCLINE; DRUG CARRIER; HESKA; PLATELET DERIVED GROWTH FACTOR; POLITEF; SOMATOMEDIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BIOCOMPATIBILITY; CHRONIC INFLAMMATION; DOG; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; HUMAN; IMPLANT; INFECTION; NONHUMAN; PERIODONTAL DISEASE; PHASE TRANSITION; REVIEW;

EID: 0031712570     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.9.1483     Document Type: Review

References (37)